Triptorelin
- Generic Name
- Triptorelin
- Brand Names
- Decapeptyl, Trelstar, Triptodur
- Drug Type
- Small Molecule
- Chemical Formula
- C64H82N18O13
- CAS Number
- 57773-63-4
- Unique Ingredient Identifier
- 9081Y98W2V
- Background
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). Possessing greater potency than endogenous LHRH, triptorelin reversibly represses gonadotropin secretion. After chronic, continuous administration, this agent effects sustained decreases in LH and FSH production and testicular and ovarian steroidogenesis. Serum testosterone concentrations may fall to levels typically observed in surgically castrated men.
- Indication
Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
- Associated Therapies
- Controlled ovarian hyperstimulation therapy
Dydrogesterone, Cetrorelix Acetate and Triptorelin in Intra Cytoplasmic Sperm Injection Outcomes
- Conditions
- IVF
- Interventions
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 387
- Registration Number
- NCT05972902
- Locations
- 🇪🇬
Beni-suef university Hospital, Banī Suwayf, Beni Suef, Egypt
A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2023-06-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 220
- Registration Number
- NCT05896566
- Locations
- 🇫🇷
Gustave Roussy Cancer Center, Villejuif, France
🇩🇪HELIOS Klinikum Berlin Buch, Berlin, Germany
🇩🇪Praxisklinik Krebsheilkunde formerly MediOnko-Institut GbR, Berlin, Germany
Dose Escalation For INtraprostatic LEsions
- Conditions
- Prostatic Neoplasms
- Interventions
- Radiation: Prostate SBRT with Focal Boost
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 54
- Registration Number
- NCT05851547
- Locations
- 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia
- Conditions
- Neoadjuvant Endocrine TherapyBreast Cancer
- Interventions
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-04-06
- Lead Sponsor
- Blokhin's Russian Cancer Research Center
- Target Recruit Count
- 300
- Registration Number
- NCT05800197
- Locations
- 🇷🇺
Blokhin's Russian Cancer Research Center, Moscow, Russian Federation
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate
- Conditions
- Locally Advanced Prostate CancerAdvanced Prostate CancerMetastatic Prostate Cancer
- Interventions
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 195
- Registration Number
- NCT05590793
- Locations
- 🇨🇳
Beijing Hospital, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, China
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Regina Elena Cancer Institute
- Target Recruit Count
- 146
- Registration Number
- NCT05557604
- Locations
- 🇮🇹
Ifo Regina elena, Rome, Lazio, Italy
🇮🇹Regina Elena National Cancer Institute, Rome, Italy
🇮🇹ifo Regina Elena, Rome, RM, Italy
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 147
- Registration Number
- NCT05458856
- Locations
- 🇧🇪
Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
🇧🇪UZ Antwerpen, Edegem, Belgium
🇧🇪CHU de Liège - Domaine Universitaire du Sart Tilman - Urologie, Liège, Belgium
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES
- Conditions
- Infertility
- Interventions
- Drug: 10000 IU hCG (Choriomon5000 IU; IBSA)
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Alexandria University
- Target Recruit Count
- 160
- Registration Number
- NCT05397795
Use of GnRHa During Chemotherapy for Fertility Protection
- Conditions
- Breast Cancer FemaleAcute LeukemiaLymphomaOsteosarcomaSoft Tissue SarcomaEwing Sarcoma
- Interventions
- Drug: Sodium Chloride solution 0.9%
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Kenny Rodriguez-Wallberg
- Target Recruit Count
- 500
- Registration Number
- NCT05328258
- Locations
- 🇸🇪
Karolinska Univeristy Hospital, Breast Centre, Stockholm, Sweden
🇸🇪Department of Oncology, Skåne University Hospital, Lund, Sweden
🇸🇪Karolinska University Hospital, Hematology, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.